Allogene Therapeutics, Inc. (NASDAQ:ALLO) Receives Average Rating of “Moderate Buy” from Brokerages

Allogene Therapeutics, Inc. (NASDAQ:ALLO) has received a consensus rating of “Moderate Buy” from the ten analysts that are presently covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a hold recommendation and nine have assigned a buy recommendation to the company. The average 12-month price target among analysts that have updated their coverage on the stock in the last year is $9.73.

A number of equities research analysts recently weighed in on the stock. Piper Sandler lowered their price objective on shares of Allogene Therapeutics from $11.00 to $9.00 and set an “overweight” rating for the company in a research report on Thursday, November 14th. HC Wainwright reiterated a “buy” rating and set a $9.00 price target on shares of Allogene Therapeutics in a research report on Friday, November 8th. Finally, William Blair reissued an “outperform” rating on shares of Allogene Therapeutics in a report on Thursday, November 14th.

Insider Buying and Selling at Allogene Therapeutics

In other Allogene Therapeutics news, insider Timothy L. Moore sold 14,746 shares of the company’s stock in a transaction that occurred on Monday, February 3rd. The stock was sold at an average price of $1.71, for a total value of $25,215.66. Following the completion of the sale, the insider now directly owns 250,713 shares in the company, valued at $428,719.23. This represents a 5.55 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Zachary Roberts sold 27,199 shares of the firm’s stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $1.78, for a total value of $48,414.22. Following the transaction, the executive vice president now directly owns 488,054 shares of the company’s stock, valued at $868,736.12. This represents a 5.28 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 71,067 shares of company stock valued at $131,959 in the last quarter. Corporate insiders own 24.30% of the company’s stock.

Hedge Funds Weigh In On Allogene Therapeutics

Several hedge funds have recently made changes to their positions in ALLO. Cibc World Markets Corp bought a new stake in shares of Allogene Therapeutics during the 4th quarter worth $26,000. Private Advisor Group LLC acquired a new position in shares of Allogene Therapeutics in the third quarter worth about $34,000. Algert Global LLC purchased a new position in shares of Allogene Therapeutics in the second quarter worth approximately $35,000. MML Investors Services LLC acquired a new stake in shares of Allogene Therapeutics during the third quarter valued at approximately $56,000. Finally, EP Wealth Advisors LLC lifted its position in shares of Allogene Therapeutics by 125.6% in the 3rd quarter. EP Wealth Advisors LLC now owns 24,475 shares of the company’s stock valued at $69,000 after acquiring an additional 13,625 shares in the last quarter. Institutional investors and hedge funds own 83.63% of the company’s stock.

Allogene Therapeutics Price Performance

Allogene Therapeutics stock opened at $1.48 on Thursday. Allogene Therapeutics has a 12 month low of $1.47 and a 12 month high of $5.78. The company has a fifty day moving average price of $1.99 and a two-hundred day moving average price of $2.41. The company has a market cap of $310.31 million, a PE ratio of -0.95 and a beta of 0.83.

Allogene Therapeutics Company Profile

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL).